Journal
FRONTIERS IN PHARMACOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2022.864768
Keywords
QSP; MID3; dose prediction; mAb; biotherapeutic; mechanistic PKPD
Categories
Ask authors/readers for more resources
The application of model-informed drug discovery and development (MID3) approaches in the early stages of drug discovery can help determine drug feasibility, prioritize targets, and define optimal drug properties. However, applying MID3 in early discovery can be challenging due to a lack of pharmacokinetic (PK) and pharmacodynamic (PD) data. Early Feasibility Assessment (EFA) uses mechanistic PKPD models and readily available data to make effective dose predictions.
The application of model-informed drug discovery and development (MID3) approaches in the early stages of drug discovery can help determine feasibility of drugging a target, prioritize between targets, or define optimal drug properties for a target product profile (TPP). However, applying MID3 in early discovery can be challenging due to the lack of pharmacokinetic (PK) and pharmacodynamic (PD) data at this stage. Early Feasibility Assessment (EFA) is the application of mechanistic PKPD models, built from first principles, and parameterized by data that is readily available early in drug discovery to make effective dose predictions. This manuscript demonstrates the ability of EFA to make accurate predictions of clinical effective doses for nine approved biotherapeutics and outlines the potential of extending this approach to novel therapeutics to impact early drug discovery decisions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available